PTHS
Pelthos Therapeutics Inc.
Price Chart
Latest Quote
$29.00
+1.99 (+7.37%)
Current Price
| Previous Close | $27.01 |
| Open | $27.50 |
| Day High | $29.00 |
| Day Low | $27.26 |
| Volume | 34,353 |
Stock Information
| Shares Outstanding | 3.48M |
| Total Debt | $52.93M |
| Cash Equivalents | $31.98M |
| Revenue | $27.70M |
| Net Income | $-51.59M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $100.79M |
| EPS (TTM) | $-22.92 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $121.75M |
| Sales | $27.70M |
| Income | $-51.59M |
| Book/sh | $10.42 |
| Cash/sh | $9.20 |
| Employees | 92 |
Financial Ratios
| Quick Ratio | 1.75 |
| Current Ratio | 2.79 |
| Debt/Eq | 150.79 |
Returns & Margins
| ROA | -36.45% |
| ROE | -333.84% |
| Gross Margin | 75.16% |
| Operating Margin | -120.01% |
| Profit Margin | -186.23% |
Ownership
| Insider Ownership | 53.81% |
| Institutional Ownership | 35.42% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.65 |
| P/S | 3.64 |
| P/B | 2.78 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $57.71 |
Technical Indicators
| SMA20 | $26.85 |
| SMA50 | $25.56 |
| SMA200 | $26.60 |
| RSI | 61.68 |
| ATR | 1.2215 |
| Shares Float | 1.45M |
| Short Float | 2.22% |
| Short Ratio | 1.65 |
| Volatility | 3.20 |
| Rel Volume | 2.89 |
Performance History
| Week | +0.97% |
| Month | +7.41% |
| Quarter | +26.27% |
| 6 Months | +32.84% |
| YTD | -1.53% |
| Year | +132.37% |
| 10 Years | -39.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $29.00 | 46,200 |
| 2026-06-17 | $27.01 | 9,200 |
| 2026-06-16 | $28.02 | 21,000 |
| 2026-06-15 | $26.50 | 64,700 |
| 2026-06-12 | $27.50 | 1,600 |
| 2026-06-11 | $28.72 | 41,800 |
| 2026-06-10 | $27.42 | 32,100 |
| 2026-06-09 | $26.90 | 800 |
| 2026-06-08 | $26.30 | 1,900 |
| 2026-06-05 | $25.55 | 3,600 |
| 2026-06-04 | $25.86 | 6,700 |
| 2026-06-03 | $25.88 | 6,900 |
| 2026-06-02 | $26.00 | 6,200 |
| 2026-06-01 | $26.20 | 12,500 |
| 2026-05-29 | $26.47 | 10,400 |
| 2026-05-28 | $25.80 | 5,500 |
| 2026-05-27 | $26.96 | 11,000 |
| 2026-05-26 | $27.17 | 10,600 |
| 2026-05-22 | $26.66 | 12,400 |
| 2026-05-21 | $27.10 | 14,900 |
| 2026-05-20 | $27.11 | 58,700 |
| 2026-05-19 | $27.00 | 61,900 |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
đ° Latest News
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-15T12:30:00Z
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
GuruFocus.com âĸ 2026-05-14T23:01:20ZPelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-14T12:20:02Z
Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview
MarketBeat âĸ 2026-03-29T08:04:31ZPelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...
GuruFocus.com âĸ 2026-03-19T19:00:55ZPelthos Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-19T18:47:31ZPelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
Zacks âĸ 2026-03-19T11:40:02Z
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires âĸ 2025-07-10T19:57:11Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $8,636,000 | $0 | - | - |
| Cost Of Revenue | $9,365,000 | $0 | - | - |
| Total Revenue | $16,795,000 | $0 | $0 | $0 |
| Operating Revenue | $16,795,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $3,012,000 | $786,000 | $518,509 | $140,430 |
| Total Expenses | $49,225,000 | $7,571,000 | $6,862,284 | $2,318,159 |
| Other Income Expense | $-15,269,000 | $402,504 | - | - |
| Other Non Operating Income Expenses | $-14,984,000 | $39,413 | - | - |
| Net Non Operating Interest Income Expense | $-3,007,000 | $-384,000 | $-518,509 | $-140,430 |
| Interest Expense Non Operating | $3,012,000 | $786,000 | $518,509 | $140,430 |
| Operating Expense | $39,860,000 | $7,571,000 | $6,862,284 | $2,318,159 |
| Selling And Marketing Expense | $7,796,000 | - | - | - |
| General And Administrative Expense | $29,280,000 | $6,392,000 | $4,282,866 | $1,926,429 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Net Interest Income | $-3,007,000 | $-384,000 | $-518,509 | $-140,430 |
| Interest Income | $5,000 | $402,000 | - | - |
| Normalized Income | $-43,075,610 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Net Income From Continuing And Discontinued Operation | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Total Operating Income As Reported | $-32,430,000 | $-7,571,000 | $-6,862,284 | $-2,318,159 |
| Net Income Common Stockholders | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Net Income | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Net Income Including Noncontrolling Interests | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Net Income Continuous Operations | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Pretax Income | $-50,706,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Special Income Charges | $-285,000 | $363,091 | $0 | $0 |
| Interest Income Non Operating | $5,000 | $402,000 | - | - |
| Operating Income | $-32,430,000 | $-7,571,000 | $-6,862,284 | $-2,318,159 |
| Depreciation Amortization Depletion Income Statement | $1,556,000 | $0 | - | - |
| Depreciation And Amortization In Income Statement | $1,556,000 | $0 | - | - |
| Amortization Of Intangibles Income Statement | $1,556,000 | $0 | - | - |
| Depreciation Income Statement | $2,541,000 | - | - | - |
| Gross Profit | $7,430,000 | $0 | - | - |
| Per Share | ||||
| Diluted EPS | $-23.04 | $-14.27 | $-12.80 | $-2.65 |
| Basic EPS | $-23.04 | $-14.27 | $-12.80 | $-2.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $-41,610 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-45,124,000 | $-7,169,000 | $-6,862,284 | $-2,318,159 |
| Total Unusual Items | $-285,000 | $363,091 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-285,000 | $363,091 | $0 | $0 |
| Reconciled Depreciation | $2,285,000 | $0 | - | - |
| EBITDA (Bullshit earnings) | $-45,409,000 | $-7,169,000 | $-6,862,284 | $-2,318,159 |
| EBIT | $-47,694,000 | $-7,169,000 | $-6,862,284 | $-2,318,159 |
| Diluted Average Shares | $1,880,498 | $557,447 | $576,752 | $928,692 |
| Basic Average Shares | $1,880,498 | $557,447 | $576,752 | $928,692 |
| Diluted NI Availto Com Stockholders | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
| Tax Provision | $-7,387,000 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $285,000 | - | - | - |
| Amortization | $1,556,000 | $0 | - | - |
| Research And Development | $1,228,000 | $1,179,000 | $2,579,418 | $391,730 |
| Selling General And Administration | $37,076,000 | $6,392,000 | $4,282,866 | $1,926,429 |
| Other Gand A | $9,664,000 | $3,460,000 | $4,282,866 | $1,926,429 |
| Salaries And Wages | $19,616,000 | $2,932,000 | - | - |
| Other Special Charges | - | $-363,091 | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-25,270,000 | $-2,714,000 | $-6,444,552 | $-3,706,537 |
| Total Assets | $130,397,000 | $1,369,000 | $96,391 | $55,074 |
| Total Non Current Assets | $76,987,000 | $0 | $0 | $0 |
| Goodwill And Other Intangible Assets | $64,151,000 | $0 | - | - |
| Other Intangible Assets | $39,470,000 | - | - | - |
| Current Assets | $53,410,000 | $1,369,000 | $96,391 | $55,074 |
| Other Current Assets | $956,000 | $106,000 | - | - |
| Current Deferred Assets | $711,000 | $750,000 | $0 | - |
| Restricted Cash | $50,000 | $0 | - | - |
| Prepaid Assets | $1,288,000 | $0 | $0 | - |
| Inventory | $23,574,000 | $0 | - | - |
| Receivables | $8,858,000 | $0 | $0 | - |
| Accounts Receivable | $8,858,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $17,973,000 | $513,000 | $96,391 | $55,074 |
| Cash And Cash Equivalents | $17,973,000 | $513,000 | $96,391 | $55,074 |
| Cash Financial | - | $513,443 | $96,391 | $55,074 |
| Debt | ||||
| Net Debt | $13,468,000 | $1,673,000 | $1,172,294 | $485,356 |
| Total Debt | $34,828,000 | $2,186,000 | $1,268,685 | $540,430 |
| Long Term Debt And Capital Lease Obligation | $34,193,000 | $0 | - | - |
| Long Term Debt | $31,441,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $635,000 | $2,186,000 | $1,268,685 | $540,430 |
| Current Debt | - | $2,186,000 | $1,268,685 | $540,430 |
| Other Current Borrowings | - | $2,186,000 | $750,082 | $104,800 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $91,516,000 | $4,083,000 | $6,540,943 | $3,761,611 |
| Total Non Current Liabilities Net Minority Interest | $65,523,000 | $0 | $0 | $0 |
| Other Non Current Liabilities | $30,050,000 | - | - | - |
| Non Current Deferred Liabilities | $1,280,000 | $0 | - | - |
| Current Liabilities | $25,993,000 | $4,083,000 | $6,540,943 | $3,761,611 |
| Other Current Liabilities | $6,042,000 | - | - | - |
| Current Deferred Liabilities | $966,000 | $0 | - | - |
| Payables And Accrued Expenses | $14,875,000 | $1,897,000 | $4,626,311 | $2,999,306 |
| Interest Payable | $234,000 | $0 | - | - |
| Payables | $10,805,000 | $1,897,000 | $4,626,311 | $2,999,306 |
| Other Payable | $7,819,000 | - | - | - |
| Accounts Payable | $2,986,000 | $1,897,000 | $4,620,925 | $2,993,920 |
| Current Notes Payable | - | $1,455,416 | $518,603 | $435,630 |
| Tradeand Other Payables Non Current | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $38,881,000 | $-2,714,000 | $-6,444,612 | $-3,706,597 |
| Total Equity Gross Minority Interest | $38,881,000 | $-2,714,000 | $-6,444,552 | $-3,706,537 |
| Stockholders Equity | $38,881,000 | $-2,714,000 | $-6,444,552 | $-3,706,537 |
| Retained Earnings | $-64,794,000 | $-21,475,000 | $-13,519,649 | $-6,138,856 |
| Preferred Stock Equity | - | - | $60 | $60 |
| Other | ||||
| Ordinary Shares Number | $3,234,423 | $610,381 | $576,752 | $576,752 |
| Share Issued | $3,234,423 | $610,381 | $576,752 | $576,752 |
| Tangible Book Value | $-25,270,000 | $-2,714,000 | $-6,444,612 | $-3,706,597 |
| Invested Capital | $70,322,000 | $-528,000 | $-5,175,927 | $-3,166,167 |
| Working Capital | $27,417,000 | $-2,714,000 | $-6,444,552 | $-3,706,537 |
| Capital Lease Obligations | $3,387,000 | $0 | - | - |
| Total Capitalization | $70,322,000 | $-2,714,000 | $-6,444,552 | $-3,706,537 |
| Additional Paid In Capital | $103,675,000 | $18,761,000 | $7,074,646 | $2,432,148 |
| Capital Stock | $0 | $0 | $451 | $171 |
| Common Stock | $0 | $0 | $391 | $111 |
| Preferred Stock | $0 | $0 | $60 | $60 |
| Non Current Deferred Revenue | $1,280,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $2,752,000 | $0 | - | - |
| Current Deferred Revenue | $966,000 | $0 | - | - |
| Current Capital Lease Obligation | $635,000 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $3,475,000 | $0 | $645,947 | $221,875 |
| Current Accrued Expenses | $4,070,000 | $0 | - | - |
| Goodwill | $24,681,000 | $0 | - | - |
| Net PPE | $12,836,000 | $0 | - | - |
| Accumulated Depreciation | $-932,000 | $0 | - | - |
| Gross PPE | $13,768,000 | $0 | - | - |
| Leases | $5,967,000 | $0 | - | - |
| Construction In Progress | $1,509,000 | $0 | - | - |
| Other Properties | $5,028,000 | - | - | - |
| Machinery Furniture Equipment | $1,264,000 | $0 | - | - |
| Properties | $0 | $0 | - | - |
| Finished Goods | $6,582,000 | $0 | - | - |
| Work In Process | $16,556,000 | $0 | - | - |
| Raw Materials | $436,000 | $0 | - | - |
| Dueto Related Parties Current | - | $0 | $5,386 | $5,386 |
| Duefrom Related Parties Current | - | $40,400 | $0 | - |
| Dueto Related Parties Non Current | - | - | - | $0 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-30,587,000 | $-5,792,000 | $-981,031 | $-1,567,149 |
| Operating Activities | ||||
| Operating Cash Flow | $-22,590,000 | $-5,792,000 | $-981,031 | $-1,567,149 |
| Cash Flow From Continuing Operating Activities | $-22,590,000 | $-5,792,000 | $-981,031 | $-1,567,149 |
| Operating Gains Losses | - | - | $201,600 | - |
| Investing Activities | ||||
| Capital Expenditure | $-7,997,000 | - | - | - |
| Investing Cash Flow | $-5,236,000 | $0 | - | - |
| Cash Flow From Continuing Investing Activities | $-5,236,000 | $0 | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-167,000 | $0 | - |
| Issuance Of Capital Stock | $0 | $6,055,000 | $255,412 | $0 |
| Financing Cash Flow | $45,336,000 | $6,209,000 | $1,022,348 | $1,622,223 |
| Cash Flow From Continuing Financing Activities | $45,336,000 | $6,209,000 | $1,022,348 | $1,622,223 |
| Net Other Financing Charges | $27,384,000 | - | - | $1,222,223 |
| Net Common Stock Issuance | $0 | $5,888,000 | $255,412 | $0 |
| Common Stock Issuance | $0 | $6,055,000 | $255,412 | $0 |
| Other | ||||
| Repayment Of Debt | $-845,000 | $-215,000 | $0 | - |
| Issuance Of Debt | $18,591,000 | $536,000 | $766,936 | $400,000 |
| Interest Paid Supplemental Data | $19,000 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $18,023,000 | $513,000 | $96,391 | $55,074 |
| Beginning Cash Position | $513,000 | $96,000 | $55,074 | $0 |
| Changes In Cash | $17,510,000 | $417,000 | $41,317 | $55,074 |
| Proceeds From Stock Option Exercised | $206,000 | $0 | - | - |
| Common Stock Payments | $0 | $-167,000 | $0 | - |
| Net Issuance Payments Of Debt | $17,746,000 | $321,000 | $766,936 | $400,000 |
| Net Short Term Debt Issuance | $-152,000 | $321,000 | $766,936 | $400,000 |
| Short Term Debt Payments | $-845,000 | $-215,000 | $0 | - |
| Short Term Debt Issuance | $693,000 | $536,000 | $766,936 | $400,000 |
| Net Long Term Debt Issuance | $17,898,000 | $0 | - | - |
| Long Term Debt Issuance | $17,898,000 | $0 | - | - |
| Net Business Purchase And Sale | $2,761,000 | $0 | - | - |
| Sale Of Business | $2,761,000 | $0 | - | - |
| Net Intangibles Purchase And Sale | $-7,898,000 | $0 | - | - |
| Purchase Of Intangibles | $-7,898,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-99,000 | $0 | - | - |
| Purchase Of PPE | $-99,000 | $0 | - | - |
| Change In Working Capital | $-6,071,000 | $35,000 | $2,051,077 | $640,864 |
| Change In Other Working Capital | $1,646,000 | $-750,000 | - | $221,875 |
| Change In Other Current Liabilities | $-282,000 | $0 | - | - |
| Change In Other Current Assets | $345,000 | $0 | - | - |
| Change In Payables And Accrued Expense | $7,519,000 | $896,000 | $2,051,077 | $640,864 |
| Change In Accrued Expense | $6,163,000 | $-283,000 | $424,072 | $221,875 |
| Change In Payable | $1,356,000 | $1,179,000 | $1,627,005 | $418,989 |
| Change In Account Payable | $1,356,000 | $1,179,000 | $1,627,005 | $413,603 |
| Change In Prepaid Assets | $-880,000 | $-861,000 | $0 | $0 |
| Change In Inventory | $1,778,000 | $0 | - | - |
| Change In Receivables | $-16,197,000 | $0 | $0 | - |
| Changes In Account Receivables | $-8,810,000 | $0 | - | - |
| Other Non Cash Items | $2,730,000 | $329,000 | $2,615,452 | $140,430 |
| Stock Based Compensation | $5,461,000 | $1,799,000 | $1,733,233 | $110,146 |
| Unrealized Gain Loss On Investment Securities | $14,984,000 | $0 | - | - |
| Asset Impairment Charge | $1,340,000 | $0 | - | - |
| Depreciation Amortization Depletion | $2,285,000 | $0 | - | - |
| Depreciation And Amortization | $2,285,000 | $0 | - | - |
| Amortization Cash Flow | $1,556,000 | $0 | - | - |
| Amortization Of Intangibles | $1,556,000 | $0 | - | - |
| Depreciation | $729,000 | $0 | - | - |
| Net Income From Continuing Operations | $-43,319,000 | $-7,955,000 | $-7,380,793 | $-2,458,589 |
Fetched: 2026-06-18